Max Planck Institute, Germany's highly regarded research institute, reported new research on Anle138b, a chemical which prevents clumping of synunclein protein in mice. Anie138b reduces the rate of growth of the alpha-synuclein protein deposits and delays nerve cell degeneration to a yet unprecedented degree. As a consequence, mice treated with this agent remain disease-free for longer than non-medicated controls.

“With Anle138b, we may have the first representative of a new class of neuroprotective agents allowing to retard or even halt the progression of conditions such as Parkinson's or Creutzfeldt-Jakob disease,” ..........

The next step is phase I safety studies, so there is still a long way to go.

The study summary can be seen on the Max-Planck-Gesellschaft site (mpg.de/en).

Very interesting news!

Here's the link: http://www.mpg.de/7115196/Parkinson-therapy

Thanks Tupelo3.